The Provincial Drug Administration held a symposium at our company to support the development of enterprises specializing in "two products and one medical device."

Release date:

2020-09-18

On August 12, during the height of summer, the Provincial Drug Administration held a symposium at our company to support the development of enterprises specializing in "two products and one medical device." Attendees included Wang Hong and Lan Wengchi, Deputy Directors of the Provincial Drug Administration; relevant officials from the Provincial Drug Administration's Departments of Pharmaceutical Distribution, Medical Device Management, and Production Supervision; Vice Mayor Xu Hui; and over 40 representatives from 15 pharmaceutical manufacturers, 3 medical device producers, and two pharmaceutical wholesale-retail chain headquarters based in our city. General Manager Xie Wenbo took the lead in briefing the attending leaders on our company's development progress. He then raised five key issues—namely, the market launch and sales of active pharmaceutical ingredients, batch changes in production lines, filing procedures, reporting protocols, and the renewal of the "Production License"—seeking guidance from the officials present. After carefully listening to reports from multiple pharmaceutical and medical device companies, the provincial drug administration officials provided detailed policy clarifications right on the spot. Vice Mayor Xu Hui delivered a speech, expressing gratitude to the provincial drug administration officials for braving the sweltering heat to conduct on-site consultations and address enterprises' concerns, particularly highlighting their extensive efforts during the COVID-19 pandemic. He emphasized that, under the guidance of the provincial bureau, the Liaoyuan Branch should actively contribute to the healthy growth of Liaoyuan's pharmaceutical industry. Additionally, he urged all pharmaceutical and medical device companies to promptly review and thoroughly implement the requirements, solutions, and measures proposed by the research team, always prioritizing the safety and quality of medicines above all else. By doing so, they can continuously enhance product quality and safety standards, ensuring that the public has access to reliable, high-quality medications.

General Manager Xie Wenbo took the lead in briefing the attending leaders on our company's development progress, and then sought their guidance on five key issues: the market launch and sales of active pharmaceutical ingredients, batch changes in production lines, filing procedures, reporting protocols, and the renewal of the "Production License." The leaders from the Provincial Drug Administration subsequently… After carefully listening to reports from multiple pharmaceutical and medical device manufacturing companies, detailed policy explanations were provided on-site.

Vice Mayor Xu Hui delivered a speech: "We thank the leaders of the Provincial Drug Administration Bureau for braving the scorching heat to work on-site, providing valuable guidance and answering enterprises' questions—especially their extensive efforts during the COVID-19 prevention and control period. We hope that the Liaoyuan Branch, under the guidance of the Provincial Drug Administration Bureau, will actively contribute to the healthy development of Liaoyuan's pharmaceutical industry. At the same time, we urge all pharmaceutical and medical device companies to promptly review and thoroughly implement the requirements, solutions, and measures proposed by the research team, always prioritizing the safety and quality of medicines. By continuously enhancing product quality and safety standards, we can ensure that the public has access to reliable, high-quality medications they can trust."

Keywords:

Medicines, leadership, enterprises, production, Drug Administration Bureau, vice mayor, medical devices and equipment, report, Liaoyuan

Deputy Director Mu Kezhen and a delegation from the Provincial Department of Industry and Information Technology visited our company for a research visit.

Jilin Province Chemical Pharmaceutical Industry Technology Innovation Strategic Alliance Development Seminar, 2016-08-20